102 related articles for article (PubMed ID: 3043919)
1. [Tumor markers. Their current diagnostic status].
Kudlacek S
Wien Med Wochenschr; 1988 May; 138(10):228-42. PubMed ID: 3043919
[TBL] [Abstract][Full Text] [Related]
2. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
[TBL] [Abstract][Full Text] [Related]
3. [Limitation of clinical usefulness of tumor marker].
Ishii M
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1139-45. PubMed ID: 7544963
[TBL] [Abstract][Full Text] [Related]
4. The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
Schlag PM
Oncologist; 1998; 3(5):VI-VII. PubMed ID: 10388128
[TBL] [Abstract][Full Text] [Related]
5. Tumor markers.
Seleznick MJ
Prim Care; 1992 Dec; 19(4):715-26. PubMed ID: 1281552
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
7. How to integrate serum tumor markers into clinical oncologic practice.
van Dalen A
Nutrition; 1995; 11(5 Suppl):489-91. PubMed ID: 8748205
[TBL] [Abstract][Full Text] [Related]
8. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
9. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
10. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
12. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
13. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
14. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
15. A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection.
Sun Z; Fu X; Zhang L; Yang X; Liu F; Hu G
Anticancer Res; 2004; 24(2C):1159-65. PubMed ID: 15154641
[TBL] [Abstract][Full Text] [Related]
16. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers as a means of cancer diagnosis--expectations and problems].
von Broen B
Z Gesamte Inn Med; 1987 Jul; 42(14):377-82. PubMed ID: 3314200
[TBL] [Abstract][Full Text] [Related]
18. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
19. [The use of monoclonal antibodies in the evaluation of the aggressiveness of tumors of the bladder].
Ravery V; Popov Z; Bellot J; Abbou CC; Chopin DK
Ann Urol (Paris); 1993; 27(1):45-50. PubMed ID: 8470880
[TBL] [Abstract][Full Text] [Related]
20. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
